Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine

Cancer Research

Volumn 71, Issue 17, 2011, Pages 5827-5837

  Hangalapura, Basav N ^a   Oosterhoff, Dinja ^a   De Groot, Jan ^a   Boon, Louis ^b   Tuẗing, Thomas ^c   Van Den Eertwegh, Alfons J ^a   Gerritsen, Winald R ^a   Van Beusechem, Victor W ^a   Pereboev, Alexander ^d   Curiel, David T ^e   Scheper, Rik J ^a   De Gruijl, Tanja D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BIOCEROS   (Netherlands)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GLYCOPROTEIN P 15095; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TYROSINASE RELATED PROTEIN 2; TYROSINASE RELATED PROTEIN 2[180-188]; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL SUSPENSION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE TARGETING; IMMUNOGENICITY; IN VITRO GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE; INTERFERON PRODUCTION; LYMPH NODE; MACROPHAGE; MELANOMA; MOUSE; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TRANSGENE; TUMOR IMMUNITY; TUMOR MODEL; TUMOR VOLUME; VACCINATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD40; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; CD40 LIGAND; DENDRITIC CELLS; LYMPH NODES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SKIN NEOPLASMS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 80052251198     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0804     Document Type: Article

References (49)

1. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009;15:2531-40.
2. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005;23:1407-13. (Pubitemid 41679393)
3. Fay JW, Palucka AK, Paczesny S, Dhodapkar M, Johnston DA, Burkeholder S, et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor- derived dendritic cells. Cancer Immunol Immunother 2006;55:1209-18. (Pubitemid 43992047)
4. Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol 2005;17:170-4. (Pubitemid 40343104)
5. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007;7:790-802. (Pubitemid 47480309)
6. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 2008;29:319-24.
7. Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 2005;65:7007-12. (Pubitemid 41060741)
8. Johnson TS, Mahnke K, Storn V, Schonfeld K, Ring S, Nettelbeck DM, et al. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule. Clin Cancer Res 2008;14:8169-77.
9. Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, et al. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Clin Cancer Res 2009;15:4612-21.
10. Adam C, Mysliwietz J, Mocikat R. Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine. J Transl Med 2007;5:16.
11. Breckpot K, Aerts JL, Thielemans K. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 2007;14:847-62. (Pubitemid 46780068)
12. Altin JG, Parish CR. Liposomal vaccines-targeting the delivery of antigen. Methods 2006;40:39-52. (Pubitemid 44415497)
13. Kretz-Rommel A, Qin F, Dakappagari N, Torensma R, Faas S, Wu D, et al. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother 2007;30:715-26. (Pubitemid 47480755)
14. Lasarte JJ, Casares N, Gorraiz M, Hervas-Stubbs S, Arribillaga L, Mansilla C, et al. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol 2007;178:748-56. (Pubitemid 46098855)
15. de Gruijl TD, Luykx-de Bakker SA, Tillman BW, van den Eertwegh AJ, Buter J, Lougheed SM, et al. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol 2002;169:5322-31. (Pubitemid 35217206)
16. Brandao JG, Scheper RJ, Lougheed SM, Curiel DT, Tillman BW, Gerritsen WR, et al. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 2003; 21:2268-72. (Pubitemid 36561319)
17. Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res 2000;60:5456-63.
18. Sloan JM, Kershaw MH, Touloukian CE, Lapointe R, Robbins PF, Restifo NP, et al. MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells. Cancer Gene Ther 2002;9:946-50. (Pubitemid 35278567)
19. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 2008;31:294-309. (Pubitemid 351441001)
20. Santosuosso M, McCormick S, Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 2005;18:283-91. (Pubitemid 41106007)
21. Abe S, Okuda K, Ura T, Kondo A, Yoshida A, Yoshizaki S, et al. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J Gene Med 2009;11:570-9.
22. Noureddini SC, Curiel DT. Genetic targeting strategies for adenovirus. Mol Pharm 2005;2:341-7. (Pubitemid 41503674)
23. Pereboev AV, Nagle JM, Shakhmatov MA, Triozzi PL, Matthews QL, Kawakami Y, et al. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther 2004;9:712-20. (Pubitemid 38660424)
24. Huang D, Pereboev AV, Korokhov N, He R, Larocque L, Gravel C, et al. Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells. Gene Ther 2008;15:298-308. (Pubitemid 351223466)
25. Steitz J, Bruck J, Knop J, Tuting T. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism. Gene Ther 2001;8:1255-63. (Pubitemid 32780814)
26. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
27. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277-86. (Pubitemid 28357756)
28. Mendiratta SK, Thai G, Eslahi NK, Thull NM,Matar M, Bronte V, et al. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res 2001;61:859-63. (Pubitemid 32174392)
29. Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 2002;188:177-82. (Pubitemid 35398875)
30. Leitch J, Fraser K, Lane C, Putzu K, Adema GJ, Zhang QJ, et al. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. J Immunol 2004;172:5200-5. (Pubitemid 38542016)
31. van Beusechem VW, van Rijswijk AL, van Es HH, Haisma HJ, Pinedo HM, Gerritsen WR. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Ther 2000;7:1940-6.
32. Tuettenberg A, Jonuleit H, Tuting T, Bruck J, Knop J, Enk AH. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy. Gene Ther 2003;10:243-50. (Pubitemid 36204413)
33. Steitz J, Tormo D, Schweichel D, Tuting T. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination. Cancer Gene Ther 2006;13:318-25. (Pubitemid 43255769)
34. Hangalapura BN, Oosterhoff D, Gupta T, de Groot J, Wijnands PG, van Beusechem VW, et al. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. Vaccine 2011;29:2313-21.
35. Samsom JN, van der Marel AP, van Berkel LA, van Helvoort JM, Simons-Oosterhuis Y, Jansen W, et al. Secretory leukoprotease inhibitor in mucosal lymph node dendritic cells regulates the threshold for mucosal tolerance. J Immunol 2007;179:6588-95.
36. Sharma S, Stolina M, Lin Y, Gardner B, Miller PW, Kronenberg M, et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999;163:5020-8. (Pubitemid 29501270)
37. Kusser KL, Randall TD. Simultaneous detection of EGFP and cell surface markers by fluorescence microscopy in lymphoid tissues. J Histochem Cytochem 2003;51:5-14. (Pubitemid 36133482)
38. Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975;35:218-24.
39. Tuting T, Gambotto A, DeLeo A, Lotze MT, Robbins PD, Storkus WJ. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther 1999;6:73-80. (Pubitemid 129667761)
40. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90:1894-900. (Pubitemid 29014223)
41. BloomM.B., Perry-Lalley D.,Robbins P.F., Li Y., el-Gamil M., Rosenberg S.A., et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997;185: 453-9.
42. Wan Y, Emtage P, Zhu Q, Foley R, Pilon A, Roberts B, et al. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell Immunol 1999;198:131-8.
43. Palucka AK, Ueno H, Fay J, Banchereau J. Dendritic cells: a critical player in cancer therapy? J Immunother 2008;31:793-805.
44. Kim YS, Kim YJ, Lee JM, Han SH, Ko HJ, Park HJ, et al. CD40- targeted recombinant adenovirus significantly enhances the efficacy of DC and B cell-based anti-tumor vaccines. Hum Gene Ther 2010;21:1697-706.
45. Romani N, Thurnher M, Idoyaga J, Steinman RM, Flacher V. Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. Immunol Cell Biol 2010;88:424-30.
46. Tillman BW, de Gruijl TD, Luykx-de Bakker SA, Scheper RJ, Pinedo HM, Curiel TJ, et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol 1999;162:6378-83. (Pubitemid 29309357)
47. Hangalapura BN, Oosterhoff D, Aggarwal S, Wijnands PG, van de Ven R, Santegoets SJ, et al. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus. J Immunother 2010;33:706-15.
48. Lore K, Adams WC, Havenga MJ, Precopio ML, Holterman L, Goudsmit J, et al. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 2007;179:1721-9.
49. Meier O, Boucke K, Hammer SV, Keller S, Stidwill RP, Hemmi S, et al. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J Cell Biol 2002;158:1119-31.